AGP Picks
View all

Florida Finance Today: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Florida Finance Today.

Press releases published on April 22, 2026

Military Families Spend Weeks Planning PCS Moves. This Free Tool Does It in Minutes
Our Children Have Rights & Cornerstone Connections  Announce Partnership, Expand Connecting H.O.P.E.
Meteora Capital to Attend Uncorrelated Puerto Rico 2026
UHI Medical Clinic Marks Earth Day with New Commitments to Advance Sustainable Outpatient Care using My Green Doctor
Luxury Aircraft Solutions Launches Private Jet Charter Platform With Human-First Service
KOA Launches Integration Between K2 KampSight® and Wild Energy’s Smart Utility Metering Platform
Exicure Announces Co-Development Agreement with Adbiotech for Burixafor (GPC-100)
Elevra Lithium Quarterly Activities Report
HLG Launches Global Ancestry Index Amid Surging Appetite for Emigration
Rogers Communications Announces Voting Results from Annual General Meeting of Shareholders
Mirastar Federal Credit Union Launches Community Needs Assessment Survey to Deepen Community Listening and Advance Inclusive Financial Solutions
The Elmet Group Co. Announces Pricing of Upsized Initial Public Offering
Univest Securities, LLC Ranked 5th in the Q1 2026 U.S. PIPE and Private Placement Markets Investment Banking League Table by Number of Transactions
Century Next Financial Corporation Reports 1st Quarter 2026 Results
The 2026 NAB Show Wraps with Proof the Future of Media and Entertainment is Expanding Beyond Broadcasting
SOUTHERN MISSOURI BANCORP REPORTS PRELIMINARY RESULTS FOR THIRD QUARTER OF FISCAL 2026; DECLARES QUARTERLY DIVIDEND OF $0.25 PER COMMON SHARE; CONFERENCE CALL SCHEDULED FOR THURSDAY, APRIL 23, AT 9:30 AM CENTRAL TIME
Press Release: Sanofi and Regeneron’s Dupixent approved in the US as the first biologic medicine for young children with uncontrolled chronic spontaneous urticaria
Communiqué de presse :  Dupixent, développé par Sanofi et Regeneron, a été approuvé aux États-Unis comme étant le premier médicament biologique pour les jeunes enfants atteints d’urticaire chronique spontanée non contrôlée
Dupixent® (dupilumab) Approved in the U.S. as the First Biologic Medicine for Young Children with Uncontrolled Chronic Spontaneous Urticaria (CSU)
TransUnion Applauds FHFA, HUD for Advancing VantageScore in Mortgage Lending

Share this page:

Sign up for:

Florida Finance Today

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.